$10.66
▲ +0.2% Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update
Overview
52-week range
$6.23
$16
43% of range
Avg surprise (last 3)
-22.4%
Avg reaction (last 2)
-6.4%
0% positive
Latest IV / EM
59%
EM ±9.2% · $11 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.35 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $-0.41 | $-0.32 | -28.1% | -10.8% | -0.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.38 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.39 | $-0.35 | -11.4% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $-0.37 | $-0.29 | -27.6% | — | -12.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.22 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.26 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.49 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.25 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.26 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.39 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13M | $11M | — | $15M | $13M | $11M | — | $15M |
| Cost of revenue | $2M | $1M | — | $2M | $2M | $1M | — | $2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-82M | $-93M | — | $-69M | $-68M | $-64M | — | $-46M |
| Net income | $-79M | $-89M | — | $-69M | $-68M | $-64M | — | $-36M |
| EPS (diluted) | $-0.35 | $-0.40 | — | $-0.38 | $-0.39 | $-0.38 | — | $-0.22 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $599M | $667M | $737M | $345M | $391M | $350M | $392M | $427M |
| Inventory | $4M | $4M | $4M | $3M | $3M | $3M | $3M | $2M |
| Total current assets | $644M | $706M | $782M | $387M | $433M | $388M | $441M | $473M |
| Total assets | $671M | $733M | $808M | $411M | $451M | $406M | $458M | $490M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $151M | $151M | $154M | $153M | $145M | $140M | $143M | $138M |
| Total equity | $520M | $582M | $654M | $258M | $306M | $266M | $315M | $352M |